Forte Biosciences (FBRX) Long-Term Deferred Tax (2017 - 2019)

Forte Biosciences (FBRX) has reported Long-Term Deferred Tax for 3 consecutive years, with $53.8 million the latest figure, recorded in Q4 2019.

• In Q4 2019, Long-Term Deferred Tax rose 28.1% year-over-year to $53.8 million; the TTM figure through Dec 2019 stood at $53.8 million (up 28.1% YoY), while the FY2019 annual figure was $53.8 million, up 28.1% from the prior year.
• Long-Term Deferred Tax grew to $53.8 million in Q4 2019 per FBRX's latest filing, from $42.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $53.8 million in Q4 2019 and bottomed at $31.8 million in Q4 2017.
• Historically, Long-Term Deferred Tax has averaged $42.5 million across 3 years, with a median of $42.0 million in 2018.
• Annual changes were most pronounced in 2018 — Long-Term Deferred Tax jumped 32.08% — and 2019, when it increased 28.1%.
• Forte Biosciences' Long-Term Deferred Tax stood at $31.8 million in 2017, then jumped by 32.08% to $42.0 million in 2018, then increased by 28.1% to $53.8 million in 2019.
• Business Quant data shows FBRX's Long-Term Deferred Tax at $53.8 million in Q4 2019, $42.0 million in Q4 2018, and $31.8 million in Q4 2017.